Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, ß-lapachone (ARQ761...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Chakrabarti, Gaurab, Silvers, Molly A., Ilcheva, Mariya, Liu, Yuliang, Moore, Zachary R., Luo, Xiuquan, Gao, Jinming, Anderson, Glenda, Liu, Lili, Sarode, Venetia, Gerber, David E., Burma, Sandeep, DeBerardinis, Ralph J., Gerson, Stanton L., Boothman, David A.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658501/
https://ncbi.nlm.nih.gov/pubmed/26602448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep17066
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki